Peptides for Muscle wasting in Dogs
The short answer
For muscle wasting in dogs, the compounds under investigation are IGF-1 LR3, MGF, BPC-157 — of which IGF-1 LR3 has the strongest evidence base, graded preliminary. Loss of muscle mass from age, disuse, chronic illness, or prolonged rest after injury. No compound described here is FDA-approved for this use in dogs, and none should be started without veterinary involvement.
About the condition
Muscle loss in dogs follows three broad routes: age-related sarcopenia, disuse atrophy after injury or surgery, and cachexia driven by chronic disease. The cause matters enormously for what to do about it, because cachexia is a metabolic process that will not respond to a growth signal the way disuse atrophy might. This is the primary research context for the IGF-1 family compounds, and it is also where their contraindications bite hardest — chronic disease in an older dog raises the possibility of an undiagnosed malignancy, in which case a growth factor is the wrong intervention.
Compounds investigated for this condition
Ranked by strength of the published evidence.
An engineered IGF-1 analogue with a half-life measured in days rather than minutes.
IGF-1 LR3 is a modified version of insulin-like growth factor 1, the hormone that mediates most of growth hormone's effects on muscle. The modification stops it binding to the carrier proteins that normally clear it, extending its active life from roughly twenty minutes to twenty or thirty hours. That potency is also the reason it demands the most caution of any compound here.
Full IGF-1 LR3 profile, dosing and safety →A locally acting muscle-repair peptide injected near the site of injury.
MGF is a splice variant of the IGF-1 gene that muscle produces in response to mechanical loading and damage. Its half-life is extremely short — around fifteen minutes — which means it acts where it is placed. That is why protocols call for injecting close to the injured muscle rather than anywhere convenient.
Full MGF profile, dosing and safety →The only peptide on this site with published canine pharmacokinetic data.
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Full BPC-157 profile, dosing and safety →Critical safety notes
These apply to the compounds listed above and should be read before considering any of them.
⚠ IGF-1 LR3: Contraindicated with active cancer
IGF-1 signalling directly drives cell proliferation. In a dog with an existing malignancy that is precisely the wrong signal. Screening before use is mandatory, not advisory.
⚠ IGF-1 LR3: Hypoglycaemia risk
IGF-1 LR3 has insulin-like activity and can lower blood glucose. Tremors, disorientation, weakness, or collapse are emergencies. Blood glucose must be monitored, and diabetic dogs require direct veterinary management.
⚠ MGF: Contraindicated with active cancer
As an IGF-1 family growth factor, MGF promotes cell proliferation. It should not be used in a dog with known or suspected malignancy.
Common questions
What peptides are used for muscle wasting in dogs?+
IGF-1 LR3, MGF, BPC-157 are the compounds investigated for muscle wasting in dogs. IGF-1 LR3 carries the strongest evidence of these, graded as preliminary evidence. None are FDA-approved for this use in dogs.
Do peptides actually help muscle wasting in dogs?+
The honest answer is that the canine evidence is limited. Loss of muscle mass from age, disuse, chronic illness, or prolonged rest after injury. The compounds investigated here have mechanistic support and, in some cases, published animal data — but controlled clinical trials in dogs with muscle wasting have not been conducted. Any use is investigational and belongs in a conversation with your veterinarian rather than a decision made independently.
References
- 1.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16174871
- 2.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 3.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 4.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 5.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 6.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 7.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.